キサンタンガム(Xanthan gum)は、化学式C35H49O29 (モノマー)、分子量は販売されているグレードにより異なり、約200万、または、1300万~5000万ほどになります。水によく溶けて粘性を示す無味無臭の物質で、増粘剤として利用されます。


キサンタンガム(Xanthan gum)は、化学式C35H49O29 (モノマー)、分子量[1063]nで、販売されているグレードにより異なり、約200万、または、1300万~5000万ほどになります。水によく溶けて粘性を示す無味無臭の物質です。






Resource ThickenUp Clear improves the safety of swallow without increasing residue providing a viscosity-dependent therapeutic effect for patients with oropharyngeal dysphagia. At nectar viscosity, the effect is due to intrinsic texture properties, spoon-thick viscosity adding changes in swallow physiology.





Groups of 4 male and 4 female beagle dogs each were fed 0, 0.25, 0.37 and 1.0 g/kg/day of xanthan gum in the diet for 2 years starting at 4–8 months of age. No differences from control dogs were seen in the treated dogs with respect to survival, food intake, body weight gain, electrocardiograms, blood pressures, hemograms, gross necropsy observations, organ weights or histopathologic observations. Blood urea nitrogen was elevated at several test intervals for one high-level male.


ビーグル犬のオス4匹とメス4匹のグループに、生後4〜8か月から2年間、0、0.25、0.37、1.0 g / kg /日のキサンタンガムを与えました。 生存率、摂餌量、体重増加、心電図、血圧、ヘモグラム、肉眼的剖検観察、臓器重量または組織病理学的観察に関して、対照犬との違いは治療犬に見られなかった。 1匹のオスに関して、血中尿素窒素がいくつかの試験間隔で上昇したとのことです。





Thirty-two patients were enrolled in this study; 28 completed. The diurnal intraocular pressure as well as the 08:00 trough and +2 hour post dosing pressures were statistically equal between groups, although a trend to a lower mean pressure was observed in the TXE (17.9 ± 3.2mmHg) compared to the TXG (18.6 ± 3.4mmHg) group. However, eight hours after dosing the pressure was 17.5 ± 3.2mmHg in the TXE group and 18.9 ± 3.3mmHg in the TXG group (P = 0.0019). Safety was similar between groups, including corneal and conjunctival staining, conjunctival hyperemia graded by anterior segment photography and at the slit lamp, and unsolicited and solicited side effects.


32人の患者がこの研究に登録されました。 28人が完了しました。 TXE(17.9±3.2mmHg)とTXG(18.6±18.6± 3.4mmHg)グループで比較。投与後8時間の圧力は、TXEグループで17.5±3.2mmHg、TXGグループで18.9±3.3mmHgでした(P = 0.0019)。 安全性については、角膜・結膜の充血、前眼部写真および細隙灯での結膜充血、および、未確認の副作用を含め、双方のグループ間で類似していた、とあります。





A total of 28 patients with mild to moderate dry eye were included in the per protocol analysis. TBUT was similar between groups at baseline (chondroitin sulfate and xanthan gum [CS/XG] group, 5.2 ± 2.3; Systane® group, 4.7 ± 2.6; P = 0.488), after 2 months of treatment, TBUT was still similar in both groups (CS/XG group, 6.1 ± 2.5; Systane® group, 7.3 ± 2.5; P = 0.088). Baseline OSDI was similar between the groups (CS/XG group, 18.8 ± 5.3; Systane® group, 19.8 ± 7.1; P = 0.810), but after 2 months of treatment, the OSDI was significantly lower in the CS/XG group (6.7 ± 5.7 versus 10.8 ± 6.4; P = 0.049). An adverse event was present in the CS/XG group, but it was not related to the treatment.





Chitosan/Xanthan Gum Based Hydrogels as Potential Carrier for an Antiviral Drug: Fabrication, Characterization, and Safety Evaluation


Xanthan gum: Safety evaluation by two-year feeding studies in rats and dogs and a three-generation reproduction study in rats


Efficacy and safety of chondroitin sulfate/xanthan gum versus polyethylene glycol/propylene glycol/hydroxypropyl guar in patients with dry eye


The effects of a xanthan gum-based thickener on the swallowing function of patients with dysphagia


The safety and efficacy of timolol 0.5% in xanthan gum versus timolol gel forming solution 0.5%



Posted by Medic